Postoperative VMAT was feasible after aortic-allograft tracheal reconstruction for adenoid cystic carcinoma
Four patients completed 54 Gy after airway reconstruction without graft-related toxicity or local recurrence during early follow-up.
Latest research
Search the archiveBone SABR preserved quality of life through one year in BONY-M
Quality of life remained stable after 30–37.5 Gy in three fractions, while symptomatic patients achieved 59% pain response at 24 weeks.
Longer palliative RT courses were associated with substantially more lymphopenia
Compared with 8 Gy in one fraction, five- and ten-fraction regimens were associated with approximately two- and threefold higher odds of lymphopenia.
Sequential hypofractionation improved locoregional control in locally advanced NSCLC
Sequential 55 Gy in 20 fractions achieved 62% three-year locoregional control, outperforming conventionally fractionated sequential chemoradiotherapy without greater toxicity.
One-week HDR brachytherapy shortened cervical cancer treatment without higher reported toxicity
Compressing three HDR brachytherapy fractions into one week shortened overall treatment time and increased early complete response without improving survival.
Hemorrhagic colitis developed during proton therapy after intensive neuroblastoma treatment
A child developed hemorrhagic colitis after only 12.6 Gy(RBE), suggesting preceding intensive systemic therapy may increase bowel vulnerability.
Surgery plus adjuvant RT and definitive RT produced similar survival in advanced head and neck cancer
After propensity matching, overall survival was similar between surgery plus adjuvant RT and definitive RT, while disease-control differences remained non-significant.
Whole-heart dose concealed high cardiac substructure exposure in left-sided lung radiotherapy
Despite a mean whole-heart dose below 9 Gy, eleven cardiac substructures averaged above 10 Gy, and targeted replanning substantially reduced coronary exposure.
Tumor Y-chromosome loss was associated with a radioresistant phenotype across cancers
Loss of the Y chromosome tracked with greater cancer-cell survival after irradiation and worse outcomes in selected radiotherapy-treated male patients.
Online adaptive proton SBRT was feasible in the phase I PARTY trial
All 50 proton SBRT fractions were completed, with online adaptation used in 84% to restore target coverage or resolve OAR violations.
Ovary–PTV distance defined where ovarian dose prediction became unreliable
Random forest best predicted ovarian dose after transposition, but all models deteriorated sharply when ovaries lay within approximately 17 mm of the PTV.
FDVH-guided re-optimization improved RapidPlan prostate VMAT plans
Patient-specific feasibility guidance improved target homogeneity and reduced rectal low-dose exposure after automated RapidPlan optimization.
ASTRO 2026 Preview. Low-Dose Radiotherapy for Knee Osteoarthritis: The Pain Question Is Nearly Settled. The Structural Claim Is Not.
A sham-controlled randomized trial presented at ASTRO 2025 gave low-dose radiotherapy its first credible positive result and vindicated the dose objection to the earlier negative trials. The ASTRO 2026 presentation attempts something considerably harder: structural and long-term clinical endpoints.
Enhanced MLC modeling did not outperform optimized DLG modeling for single-isocenter SRS
Enhanced leaf and optimized DLG models produced similarly accurate SRS dose calculations, with DLG showing a small QA advantage.
ICI timing did not change pathological response when neoadjuvant ESCC backbones were matched
Concurrent and consolidation ICI produced similar pathological response rates once analyses were restricted to neoadjuvant chemoradiotherapy studies.